- About us
- News & Publications
MerLion Pharmaceuticals is addressing one of the most pressing problems in today’s medicine: the need for novel antibiotics to combat the alarming spread of antibiotic-resistant bacteria.
The company is solely focused on the development of Finafloxacin, a next-generation fluoroquinolone antibiotic with distinct properties – the safest and fastest acting fluoroquinolone ever developed.
The compound has demonstrated superior safety and efficacy in numerous clinical trials in commercially attractive indications.
Following successfully Phase III trials, Xtoro™ (liquid suspension formulation of finafloxacin) has received marketing approval from FDA for the treatment of Acute Otitis Externa (AOE).
Finafloxacin has successfully completed Phase II trials in systemic formulations (iv and oral) for the treatment of complicate urinary tract infections (cUTI).
MerLion is working with UK’s Defence Science and Technology Laboratory (Dstl) on a US Government Department of Threat Reduction Agency (DTRA) funded programme for the use of finafloxacin against a number of pathogens that are considered potential bio-weapon threats.
Finafloxacin is available for acquisition and in-licensing, including worldwide development and marketing rights.